Omega Diagnostics Group PLC Payment received (9314R)

TIDMODX

RNS Number : 9314R

Omega Diagnostics Group PLC

11 July 2022

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Payment received

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health products, announces that it has received payment from Abingdon Health plc ("Abingdon") in relation to the manufacture and supply of AbC-19(TM) Rapid tests, a COVID-19 lateral flow antibody test.

The payment was due under the Supply of Goods contract announced on 19 October 2020, and was made following confirmation from Abingdon that a cash payment had been received from the Department for Health & Social Care ("DHSC") on 7 July 2022, as part of a settlement agreement relating to outstanding invoices due from DHSC to Abingdon.

Contacts:

 
 Omega Diagnostics Group PLC                                       www.omegadx.com 
 Jag Grewal, Chief Executive Officer                               via Walbrook PR 
 Chris Lea, Chief Financial Officer 
 
 finnCap Ltd                                                    Tel: 020 7220 0500 
 Geoff Nash/Edward Whiley/George Dollemore 
  (Corporate Finance) 
 Alice Lane/ Harriet Ward (ECM) 
 
 Walbrook PR Limited                    Tel: 020 7933 8780 or omega@walbrookpr.com 
 Paul McManus                                                   Mob: 07980 541 893 
 Lianne Applegarth                                              Mob: 07584 391 303 
 Sam Allen                                                      Mob: 07502 558 258

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 70 countries and specialise in the areas of health and nutrition and global health.

www.omegadx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCDDGDRXDBDGDG

(END) Dow Jones Newswires

July 11, 2022 02:00 ET (06:00 GMT)

Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Mar 2024 to Apr 2024